Trial intelligence / Profile preview

Ranibizumab for diabetic macular edema: retinal function over 12 months

2011-002202-70Phase 4Completed

Sponsor
Universitätsklinikum Schleswig-Holstein
Start
Jun 2011
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Change in macular retinal function by multifocal ERG at 12 months. Started Jun 2011; status: completed.

02

Drugs

ranibizumab
03

Conditions

diabetic macular edema (DME)

Beyond the preview

Go deeper on 2011-002202-70.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-002202-70.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call